Zydus Lifesciences Limited (BOM:532321)
India
· Delayed Price · Currency is INR | Market Cap | 920.35B |
| Revenue (ttm) | 260.89B |
| Net Income (ttm) | 49.38B |
| Shares Out | n/a |
| EPS (ttm) | 49.07 |
| PE Ratio | 18.64 |
| Forward PE | 21.49 |
| Dividend | 11.00 (1.21%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 20,974 |
| Average Volume | 35,859 |
| Open | 895.95 |
| Previous Close | 896.55 |
| Day's Range | 895.95 - 917.80 |
| 52-Week Range | 797.05 - 1,059.00 |
| Beta | n/a |
| RSI | 52.46 |
| Earnings Date | Feb 9, 2026 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi... [Read more]
Financial Performance
In fiscal year 2025, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.
Financial StatementsNews
Top stocks for trade today, March 2: Tata Motors, Hero MotoCorp, Zydus Lifesciences, Aurobindo Pharma, Vedanta and more
Indian stock markets are expected to track a busy news flow on March 2, with developments across pharmaceuticals, infrastructure, auto...
Zydus Lifesciences secures USFDA final approvals for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg
Zydus Lifesciences Limited has received final approvals from the United States Food and Drug Administration (USFDA) for two generic products...
Zydus to launch semaglutide injection in India
Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after.
Top stocks to watch today, Feb 26: NALCO, Hindustan Zinc, Zydus Lifesciences, Tata Power, Waaree Energies and more
Indian markets on February 26 are expected to react to company-specific announcements across metals, pharmaceuticals, renewable energy, financial services, and...
Zydus Lifesciences to launch Semaglutide Injection in India
Zydus Lifesciences Limited, an innovation-led life sciences company with a strong international presence, is set to launch Semaglutide Injection in...
Zydus Lifesciences lunches Anyra, India’s first indigenously developed Aflibercept 2 mg biosimilar for retinal diseases
Zydus Lifesciences Ltd., an innovation-led global life sciences company, has announced the launch of Anyra™, India’s first indigenously developed biosimilar...
Zydus Lifesciences launches India’s first affordable OPEP device PEPAIR
Zydus Lifesciences Limited, an innovation-led global life sciences company, has announced the launch of PEPAIR™, India’s first affordable Oscillating Positive...
Zydus Lifesciences Ltd (BOM:532321) Q3 2026 Earnings Call Highlights: Strong Revenue Growth ...
Zydus Lifesciences Ltd (BOM:532321) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Costs
Q3 2026 Zydus Lifesciences Ltd Earnings Call Transcript
Q3 2026 Zydus Lifesciences Ltd Earnings Call Transcript
Zydus Lifesciences settles US Patent Litigation with Astellas Pharma over Myrbetriq, to pay USD 120 million
Zydus Lifesciences has announced a major settlement agreement with Astellas Pharma in relation to the US patent litigation surrounding Myrbetriq®...
Zydus Life shares jump over 4% as Q3 Revenue surge 30.3% YoY to Rs 6,864.5 crore, net profit rises 1.8%
Zydus Lifesciences shares rallied more than 4% after the company reported a solid year-on-year performance for the third quarter ended...
Zydus Lifesciences Q3 Results: Revenue jumps 30.3% YoY to Rs 6,864.5 crore, net profit up 1.8%
Zydus Lifesciences reported a solid year-on-year performance for the third quarter ended December 31, 2025, with strong growth in revenue...
Top Q3 results today, Feb 9: BSE, Zydus Lifesciences, Aurobindo Pharma, Pfizer and more to announce earnings
The December-quarter earnings season gathers pace on February 9, with several listed companies scheduled to announce their Q3 FY26 financial...
Zydus Lifesciences receives USFDA tentative approval for Dapagliflozin Tablets
Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has received tentative approval from the United States Food and Drug...
Stocks to watch today, Jan 27: Infosys, Adani Enterprises, Zydus Lifesciences, ONGC, Bank of Baroda and more
Indian benchmark equity indices are set to open higher at the start of the week after a long weekend, supported...
Zydus Lifesciences launches world’s first biosimilar of Nivolumab, ‘Tishtha’ in India
Zydus Lifesciences Limited has marked a major milestone in India’s oncology landscape with the launch of Tishtha™, the world’s first...
Ardelyx (ARDX) Surges on Potential Acquisition by Zydus Lifesciences
Ardelyx (ARDX) Surges on Potential Acquisition by Zydus Lifesciences
Ardelyx gains on report Zydus Lifesciences in talks to purchase
Zydus Lifesciences’ US arm Sentynl secures FDA approval for ZYCUBO, first-ever treatment for Menkes disease
Zydus Lifesciences Limited has achieved a major global healthcare milestone after its wholly owned US subsidiary Sentynl Therapeutics Inc. announced...
Delhi HC clears Zydus biosimilar, boosting access to affordable cancer care
India News: NEW DELHI: In a significant ‘public interest’ move, the Delhi High Court has allowed Zydus Lifesciences to manufacture and sell a biosimilar of Bristo.
Zydus Lifesciences, Bioeq Sign Agreement To Commercialize NUFYMCO In US
(RTTNews) - Zydus Lifesciences Limited (ZYDUSLIFE.NS), Tuesday announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, has entered into a strategic partnership...
Zydus Lifesciences shares in focus today after High Court allows semaglutide manufacturing for exports
Shares of Zydus Lifesciences Limited were in focus in morning trade after a High Court order allowed the company to...
Zydus Lifesciences signs exclusive agreement with Myriad Genetics to launch advanced cancer genomic tests in India
Zydus Lifesciences Limited has entered into a strategic agreement with Myriad Genetics, a global leader in molecular diagnostic testing and...
Top stocks to watch today, December 16: HCL Technologies, TCS, RBL Bank, Delhivery, Zydus Lifesciences and more
Indian equities are set to begin Tuesday’s session on a cautious note, mirroring subdued global market cues. Early indicators suggest...
Zydus Lifesciences launches ‘Zyrifa’, a Denosumab biosimilar for advanced cancer-related bone complications
Zydus Lifesciences Ltd., the innovation-driven Indian healthcare company with a strong international footprint, has introduced its latest biosimilar, ‘Zyrifa’, a...